文献速递技术与安全

风险投资资金支持下FDA批准人工智能产品的预期增长

Projected Growth in FDA-Approved Artificial Intelligence Products Given Venture Capital Funding.
PubMed 文献 · J Am Coll Radiol · 2023-10-16

基于预期融资增长,FDA批准的AI产品预计将从2022年的69个增长至2035年的350个;随着新产品开发并整合入实践,AI可能改变诊断放射学的实践方式,更多AI产品整合可能激励未来AI产品的投资增加。

要点

  • 每10亿美元融资对应11.33个新FDA批准AI产品(95%CI:7.03-15.64),假设融资与获批间隔6年。
  • 2022年有69个新FDA批准产品,对应48亿美元融资。
  • 预计2035年产品年融资达308亿美元,当年新增产品350个。

核心结论

  • 基于预期融资增长,FDA批准的AI产品预计将从2022年的69个增长至2035年的350个;随着新产品开发并整合入实践,AI可能改变诊断放射学的实践方式,更多AI产品整合可能激励未来AI产品的投资增加。

研究设计与样本

  • 研究利用ACR数据科学研究所的FDA批准AI产品数据(2008-2022年)和Rock Health的AI融资数据(2013-2022年),采用6年滞后线性回归估计某年新获批产品与滞后融资(即产品年融资)的关联,并据此预测新FDA批准产品数量。

临床应用与阅片要点

  • 原文未据此给出推荐,仅指出AI可能改变诊断放射学实践,随着更多AI产品整合可能激励未来AI产品投资增加。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: Medical imaging accounts for 85% of digital health's venture capital funding. As funding grows, it is expected that artificial intelligence (AI) products will increase commensurately. The study's objective is to project the number of new AI products given the statistical association between historical funding and FDA-approved AI products.

METHODS: The study used data from the ACR Data Science Institute and for the number of FDA-approved AI products (2008-2022) and data from Rock Health for AI funding (2013-2022). Employing a 6-year lag between funding and product approved, we used linear regression to estimate the association between new products approved in a certain year, based on the lagged funding (ie, product-year funding). Using this statistical relationship, we forecasted the number of new FDA-approved products.

RESULTS: The results show that there are 11.33 (95% confidence interval: 7.03-15.64) new AI products for every $1 billion in funding assuming a 6-year lag between funding and product approval. In 2022 there were 69 new FDA-approved products associated with $4.8 billion in funding. In 2035, product-year funding is projected to reach $30.8 billion, resulting in 350 new products that year.

CONCLUSIONS: FDA-approved AI products are expected to grow from 69 in 2022 to 350 in 2035 given the expected funding growth in the coming years. AI is likely to change the practice of diagnostic radiology as new products are developed and integrated into practice. As more AI products are integrated, it may incentivize increased investment for future AI products.

来源:J Am Coll Radiol,查看原文。版权归原作者所有。

引用

  1. McNabb NK, Christensen EW, Rula EY, et al. Projected Growth in FDA-Approved Artificial Intelligence Products Given Venture Capital Funding. J Am Coll Radiol. 2023. PMID: 37843483. doi:10.1016/j.jacr.2023.08.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。